AMH may guide the selection of patient-tailored gonadotrophin starting doses for a more optimal ovarian response, and, more importantly, for reducing the clinical risks associated with excessive response.
Vaccine immunogens are typically administered with adjuvants in order to stimulate more optimal immune responses associated with protective effects.
For the fighting spirit, fatalism, and helplessness-hopelessness subscales, a revised three-point response format seemed more optimal than the original four-point response.
The aim is to guide cytokines specifically to tumor sites where they might stimulate more optimal anti-tumor immune responses while avoiding the systemic toxicities of free cytokine therapy.
The use of D70 as a dose metric may be more optimal than Davg when comparing to response, as seen by a tighter clustering of points around the curve; however, the difference is subtle.
Future research should delve into the optimal response levels even further with more precise response data and a more sophisticated analysis.
Furthermore, the lack of standardized criteria for the optimal response or residual/refractory disease makes it more challenging to use interim BM results to guide further management.
It may be the case that while patients with early-stage AD achieve sufficient response from lower-dose acetylcholinesterase inhibitors, patients with more advanced AD require higher doses to achieve an optimal response.
For example, for de novo mutations found in patients with schizophrenia, the opposite shift from less optimal to more optimal codons was observed (see more details in our response #3 to Dr. Smalheiser below), and in this case, random mutations under the same model also exhibit such a shift.
Then the modified NSGA-II is used to achieve optimal responses more accurately, and optimization outcomes of both methods are finally compared and presented.
